Hodgson Ian 4

4 · Corbus Pharmaceuticals Holdings, Inc. · Filed Feb 18, 2026

AI-generated summary of this filing

Updated Feb 18, 2026

Corbus (CRBP) COO Ian Hodgson Sells 847 Shares

What Happened

Ian Hodgson, Chief Operating Officer of Corbus Pharmaceuticals (CRBP), sold 847 shares on 2026-02-17 in an open-market/private sale. The weighted average price was $7.38 per share (range $7.37–$7.42), generating approximately $6,253 in proceeds. According to the filing, the sale was to cover tax withholding tied to RSU vesting and was not a discretionary sale (F1, F2).

Key Details

Transaction date: 2026-02-17; Filing date: 2026-02-18 (filed timely).
Shares sold: 847; weighted avg price: $7.38; price range: $7.37–$7.42; proceeds ≈ $6,253 (F2).
Reason: Sell-to-cover to satisfy tax withholding obligations on vested RSUs (mandated by issuer), not a voluntary disposition by the insider (F1).
Shares owned after transaction: Not specified in the information provided on this filing.
Other holdings: Filing notes there are 46,362 unvested RSUs subject to vesting schedules as previously reported (F3).

Context

This was a routine sell-to-cover tied to RSU settlement and tax obligations, which is common and generally not considered a signal of reduced confidence by the insider. Purchases tend to be more informative about insider sentiment; this transaction was administrative in nature.

Form 4

Period: 2026-02-17

Chief Operating Officer

Transactions

Sale
Common Stock, par value $0.0001 per share
[F1][F2][F3]
2026-02-17$7.38/sh−847$6,253→ 51,080 total

Footnotes (3)

[F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
[F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]This amount includes 46,362 unvested RSUs subject to each grant's vesting schedule as previously reported.

Signature

/s/ Meghan Houghton, attorney-in-fact for Ian Hodgson|2026-02-18

1 file